Esperion Therapeutics Q3 2025 Earnings Report

Esperion Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.06
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Esperion Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $78.33 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Esperion Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/6/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 8:00AM ET

Esperion Therapeutics (NASDAQ:ESPR) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S. Food and Drug Administration, and NILEMDO (bempedoic acid/ezetimibe), an oral fixed-dose combination therapy. Both products are indicated as adjuncts to diet and maximally tolerated statin therapy for adult patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Esperion continues to explore additional formulations and indications for its ACL inhibition platform, with clinical programs aimed at expanding patient access and optimizing long-term cardiovascular outcomes.

Headquartered in Ann Arbor, Michigan, Esperion was re-established in 2013 following the acquisition of specific cardiovascular assets from a global pharmaceutical company. The company completed its initial public offering on the NASDAQ Global Market under the ticker symbol “ESPR” and maintains research, development and commercial operations in the United States. Esperion has also pursued regulatory approvals and market launches in Europe, working to broaden its geographic footprint and engage with healthcare providers and payers worldwide.

Esperion’s leadership team is led by President and Chief Executive Officer Timothy M. Mayleben, who brings extensive experience in commercial strategy and product launches within the cardiovascular therapeutic area. Under this leadership, the company aims to further develop its pipeline, enhance patient outreach and drive adoption of oral LDL-C–lowering treatments to address the significant unmet needs in cardiovascular health management.